TOKYO, Oct 11, 2021 – (JCN Newswire) – Fujitsu Limited today announced that it has started joint clinical research with the University of Tokyo Hospital to verify the effectiveness of artificial intelligence technology to estimate abnormal heart movements based on electrocardiogram(1) data. The research is planned to commence at the University of Tokyo Hospital from October 25.
Since December 2019, Fujitsu has been making progress with research and development of proprietary AI technology(2) in collaboration with the University of Tokyo Hospital. This research draws on data from patients that have visited the University of Tokyo Hospital to date and includes approximately 630,000 pieces of electrocardiographic data and data from approximately 140,000 cardiac ultrasounds (echocardiography)(3). The initiative has been able to detect abnormal heart rhythms with high accuracy.
The AI will be used in clinical field research to estimate the presence or absence of abnormal heart movements based on the data of patients undergoing electrocardiographic procedures at the University of Tokyo Hospital. Echocardiography will be performed on patients identified by the AI to have abnormal heart movements. The effectiveness of the AI’s prediction will be confirmed by comparing doctors’ diagnoses with the AI’s predictions. Fujitsu will use this AI to detect and prevent heart disease in the early stages. This will help to strengthen Fujitsu’s vision of “Healthy Living” which promotes well-being across society.
This initiative will be introduced at Fujitsu ActivateNow 2021, a global event to be held from October 12 in online format.
Heart disease is the second leading cause of death in Japan (4), and electrocardiography, which detects abnormalities in the heart muscle and irregular pulses based on the waveform of electrical pulses in the heart, is widely used as a diagnostic tool to detect heart disease at an early stage. However, it is difficult to detect abnormalities in shape or movement of the heart with only electrocardiograms. Doctors use a stethoscope in medical practice to detect abnormal heart sounds (murmurs and arrythmia). Based on the patient’s symptoms, echocardiography is used to determine abnormalities in heart movement and shape. It is not possible to provide echocardiographic diagnostics for all patients as it can only be done in limited facilities that have specialized doctors and lab technicians. Early detection is difficult and the disease progression may be already advanced if problems are not detected. Early detection and timely treatment are crucial in the management of heart disease.
Since December 2019, in collaboration with a research group headed by Dr. Katsuhito Fujiu, Project Associate Professor, and Dr. Issei Komuro, Professor in the Department of Cardiovascular Medicine at the University of Tokyo Hospital, Fujitsu has been engaged in research and development utilizing AI to detect heart disease from electrocardiogram data, leveraging Fujitsu’s proprietary waveform analysis technology, TDA (topological data analysis) (5). Fujitsu will continue to work with a research group headed by Dr. Katsuhito Fujiu, Project Associate Professor, to validate the effectiveness of AI in medical practice to determine the presence or absence of abnormalities of cardiac function using electrocardiogram data.
Clinical Research Overview
Based on the electrocardiogram data of patients examined at the University of Tokyo Hospital, Fujitsu and the University of Tokyo Hospital will verify the effectiveness of detection of abnormal heart movement by AI.
From October 25, 2021 (Monday) to March 31, 2022 (Thursday) (Planned)
Department of Cardiovascular Medicine, the University of Tokyo Hospital
3. Clinical Research Activity: testing artificial intelligence to estimate abnormal heart movements
Fujitsu will install a server equipped with AI to detect abnormalities in heart movement at the University of Tokyo Hospital and connect it to a server that stores electrocardiogram data, analyze the patient’s electrocardiogram, and estimate the presence or absence of abnormal heart movements. Echocardiography is performed on patients the AI predicts to have abnormal heart movements, and doctors determine whether heart disease is present.
4. Division of roles
Fujitsu: Install and operate AI-powered servers
The University of Tokyo Hospital: Input of the patient’s electrocardiogram data into the AI, echocardiography if the AI suspects an abnormality, and testing the effectiveness of the AI based on the results.
Based on the results of this clinical research, Fujitsu will promote research and development of solutions that can detect abnormalities in heart motion at an early stage and contribute to the prevention of progression to serious heart disease in patients. Fujitsu will continue its research collaboration with the University of Tokyo Hospital to promote AI research and development to detect various heart diseases. Fujitsu hopes to use the results of its research to help solve medical problems facing society. It will also drive the development and deployment of technologies and services that support “Healthy Living” and increase trust.
A record of changes in the electrical potential of the heart.
(2) Research and development on their unique AI:
Conducted in accordance with the University of Tokyo Hospital Code of Ethics.
A chest ultrasound that examines the reflected waves and determines the mechanical functions of the heart, including its movement and shape.
(4 The second leading cause of deaths in Japan is
According to the “Summary of Vital Statistics”, (Ministry of Health, Labour and Welfare).
(5 TDA (Topological data Analysis):
A data analysis method that considers data as a collection of points placed in a specific space and extracts the geometric information.
Fujitsu’s Commitment to the Sustainable Development Goals (SDGs)
The Sustainable Development Goals (SDGs) adopted by the United Nations in 2015 represent a set of common goals to be achieved worldwide by 2030. Fujitsu’s mission, “To make the world more sustainable through building trust in society via innovation”, is a commitment to help realize the SDGs vision.
Fujitsu is the leading Japanese information and communication technology (ICT) company offering a full range of technology products, solutions and services. Approximately 126,000 Fujitsu people support customers in more than 100 countries. Our customers are our future. We combine our knowledge and the power ICT to help shape it. Fujitsu Limited (TSE: 6702) reported consolidated revenues of 3.6 trillion yen (US$34 billion) for the fiscal year ended March 31, 2021. For more information, please see www.fujitsu.com.
Topic: Press release summary
Source: Fujitsu Ltd
Sectors: Artificial Intel [AI], MedTech
From the Asia Corporate News Network
Copyright (c) 2021 ACN Newswire. All rights reserved. Asia Corporate News Network is a division.